PILL
PILL 2-star rating from Upturn Advisory

Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL)

Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) 2-star rating from Upturn Advisory
$11.91
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

01/09/2026: PILL (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 2 star rating for performance

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type ETF
Historic Profit 96.59%
Avg. Invested days 53
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 01/09/2026
Advertisement

Key Highlights

Volume (30-day avg) -
Beta 1.79
52 Weeks Range 3.60 - 10.53
Updated Date 06/29/2025
52 Weeks Range 3.60 - 10.53
Updated Date 06/29/2025
Advertisement

About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF

Exchange NYSE ARCA
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.